SurfSubQ - A Prospective Longitudinal Observational Study of Neurofilament Light Chain Levels and Patient Satisfaction After Subcutaneous Ocrelizumab in Multiple Sclerosis

What this Trial Is About

This research aims to evaluate participant satisfaction with subcutaneous SC administration of ocrelizumab in people with multiple sclerosis MS. Participants include those diagnosed with relapsing-remitting MS RMS or primary progressive MS PPMS according to the 2017 McDonald criteria. The study focuses on assessing satisfaction after 12 months of treatment using the Therapy Administration Satisfaction Questionnaire subcutaneous TASQ-SC. Participants will receive ocrelizumab as a subcutaneous injection for the first time as part of their routine MS therapy, following their physicians judgment and local guidelines. The study observes treatment satisfaction over a 12-month period without altering standard care. Treatment administration is monitored in accordance with usual clinical practice. Throughout the study, participants will complete satisfaction questionnaires at baseline, 6 months, and 12 months. Researchers will also measure neurofilament light chain NfL protein levels in serum at these timepoints and analyze their correlations with MS relapse, disability scale scores, previous treatments, and other factors. Safety is monitored by recording adverse events up to 12 months. The study involves regular assessments to understand the effects of ocrelizumab SC on patient satisfaction and biological markers over one year.

A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)